IJGC conversations

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Gabriel Levin to discuss Decline of Trachelectomy in Early Cervical Cancer. 

 

Dr. Gabriel Levin is a gynecologic oncologist and clinical researcher at Bar-Ilan University, and the Holy Family Hospital, Nazareth. His work focuses on real-world outcomes research, and health systems innovation in gynecologic cancers. He has authored more than 360 peer-reviewed publications and is actively involved in advancing evidence-based care through academic leadership, mentorship and international collaboration.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Alice Bergamini and Michael Seckl to discuss Management of Adult Ovarian Germ Cell Tumors. 

 

Dr. Alice Bergamini is a gynecologist at the Gynecology and Obstetrics Unit of IRCCS Ospedale San Raffaele, and a University Researcher at the Faculty of Medicine and Surgery at Vita-Salute San Raffaele University. After graduating with honors and a special mention in Medicine and Surgery from Vita-Salute San Raffaele University in 2011, she specialized in Gynecology and Obstetrics at the same university in 2017. In 2021, she completed her Ph.D. in Molecular Medicine (Clinical and Experimental Medicine curriculum).Dr. Bergamini's primary clinical interests include the diagnosis and treatment of gynecological neoplasms, particularly rare gynecological cancers.She is involved in gynecological ultrasound diagnostics, hysteroscopy, ward activities, delivery room, and obstetric/gynecological emergency care. Additionally, she conducts clinical research in gynecological oncology, serving as both principal and sub-investigator in Phase II and III clinical trials, both national and international. Dr. Bergamini is a member of EURACAN, the European Society of Gynecological Oncology (ESGO), the International Gynecological Cancer Society (IGCS), the European Network for Gynaecological Oncological Trial Groups (ENGOT) rare tumor working group, the Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), and the European Organization for the Treatment of Trophoblastic Disease (EOTTD). She is the author and co-author of numerous articles published in international scientific journals (H-Index 19) and regularly participates in national and international conferences.

Michael Seckl is a Professor of Molecular Oncology at Imperial College London, where he leads research in lung cancer and trophoblastic disease. He earned his medical degree from UCL, completed oncology training, and obtained a PhD in signal transduction from the University of London. He directs the National Trophoblastic Disease and MOGCT Centre. An international leader in trophoblastic disease, he has held key roles in ISSTD, EOTTD, and EURACAN, and serves on multiple editorial and grant committees. His work is widely funded and recognized, earning him a Fellowship of the Academy of Medical Sciences (FMedSci) in 2017.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. René Pareja to discuss Gynecologic Oncology Practice in Low & Middle Resource Settings.

 

Dr. René Pareja is a Gynecologist and Obstetrician, graduated from Universidad Pontificia Bolivariana in Medellín, Colombia in 2000; he finished his training in Gynecologic Oncology in 2003, from Pontificia Universidad Javeriana and Instituto Nacional de Cancerología in Bogotá, Colombia.

He is a minimally invasive surgeon, graduated from Corporación de Estudios de la Salud (CES) in 2013. He currently works at Astorga Oncology Clinic in Medellín and at National Cancer Institute in Bogotá, Colombia.
Dr. Pareja serves as a reviewer for more than 20 journals. He has authored or co-authored nine book chapters and more than fifty publications in peer-reviewed journals. Currently he is an Associate Editor of the International Journal of Gynaecological Cancer and is a Council member of the International Gynecological Cancer Society Council. He also serves as an international mentor for the Hospital General San Juan de Dios in Guatemala through the IGCS Global Curriculum & Mentorship Program. Some of his research has influenced how gynecologic oncologists treat cancer and has been published in important medical journals, like the New England Journal of Medicine, JAMA, and Journal of Clinical Oncology.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Domenica Lorusso to discuss ROSELLA Trial: Overall Survival Outcomes.

 

Dr. Domenica Lorusso, MD, PhD, directs the Gynaecological Oncology Unit at Humanitas Hospital, Milan, and holds a Full Professorship in Obstetrics and Gynaecology at Humanitas University, Rozzano, Milan. She has led/participated in approximately 250 phase I-IV clinical trials. Currently overseeing more than 60 studies as Principal Investigator, Dr. Lorusso also chairs the Clinical Trials Committee of the MITO Group. She serves on the Board of Directors of the GCIG and is an active member of ENGOT, where she chairs the Gynecological Cancer Academy. Additionally, she sits on the Board of Directors of the ESGO. With around 300 international oncology publications and contributions to national and international treatment guidelines, her primary objectives are to ensure optimal patient care, foster clinical research, and advance international collaborations and education in the field. Her recent work, “Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial,“ is published in the Lancet.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Emese Zsiros to discuss KEYNOTE-B96: Pembrolizumab and Weekly Paclitaxel in Ovarian Cancer.

 

Emese Zsiros, MD, PhD, FACOG, is Chair of the Department of Gynecologic Oncology and the Shashi Lele, MD Endowed Chair at Roswell Park Comprehensive Cancer Center, where she is also Professor of Oncology and co-leader of the Tumor Immunology and Immunotherapy Program.
A high-volume gynecologic oncologic surgeon and clinical investigator, Dr. Zsiros specializes in the surgical and medical treatment of ovarian, endometrial, cervical, and other gynecologic cancers, with expertise in minimally invasive surgery, immunotherapy, cell-based therapies, and innovative clinical trials. She has contributed to more than 150 clinical trials and leads research focused on overcoming treatment resistance, improving immunotherapy, and integrating artificial intelligence and data-driven approaches into personalized cancer care.
Dr. Zsiros earned her MD and PhD from the University of Debrecen in Hungary, completed her OB/GYN residency at Northwestern University, and trained in Gynecologic Oncology at the University of Pennsylvania. She joined Roswell Park in 2014 and became the institution’s first female surgical chair in 2022. Her work is driven by a commitment to surgical excellence, scientific innovation, mentorship, and improving both outcomes and quality of life for women with gynecologic cancers. Her recent work, “Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study,“ is published in the Lancet.